Peter Altman, who serves as President and Chief Executive Officer of BioCardia, Inc. (NASDAQ: BCDA), completed two separate insider purchases of the company’s common stock on March 24 and March 25, 2026, increasing his directly held position by 900 shares for a total outlay of $1,110.
On March 24, 2026, Altman acquired 600 shares in multiple trades at prices between $1.24 and $1.26, a transaction recorded at $744. The following day, March 25, 2026, he added 300 shares in several trades priced between $1.19 and $1.25, a transaction recorded at $366. Taken together, the two transactions amount to $1,110.
After these purchases, Altman directly owns 274,766 shares of BioCardia. At the time of reporting, BCDA was trading at $1.18, close to its 52-week low of $1.00, and the shares have lost 56% of their value over the trailing 12 months. The company’s market capitalization is reported at $12.4 million.
Third-party analysis cited in company coverage indicates that InvestingPro considers BioCardia undervalued according to its Fair Value assessment. Alongside that valuation view, InvestingPro Tips point to the company’s rapid cash burn and note that analysts do not expect BioCardia to be profitable in the current year. Additional ProTips and an extended Pro Research Report covering BCDA and more than 1,400 other U.S. equities are available for subscribers.
In related corporate developments, BioCardia released its financial results for the fourth quarter of 2025. The company reported a modest increase in operating expenses and a net loss as it continues to fund and advance its clinical programs. BioCardia emphasized its continued focus on the CardiAMP therapy, noting promising trial results and ongoing discussions with regulators as part of its strategic clinical work.
Following the earnings and corporate updates, the company’s stock experienced a slight decline in aftermarket trading. Company statements and reporting continue to highlight BioCardia’s commitment to progressing clinical initiatives as the central element of its recent activity.
Context and implications
The transactions by Altman represent modest insider buying by dollar value in a company with a small market capitalization. The purchases raise his direct stake but do not materially change overall ownership percentages given the size of his existing position.
Investors assessing these developments have access to valuation commentary and additional proprietary tips through InvestingPro, which also flags the company’s cash consumption and lack of expected near-term profitability as significant financial considerations.